The Central Nervous System Market Is The Second Largest Therapeutic Category And Is One Of The Fastest Growing
Posted on: Monday, 20 November 2006, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c45631) has announced the addition of "New Drug Futures: Central Nervous System Chapter" to their offering.
**Please note this chapter is taken from the "New Drug Futures" report. Please search Espicom site for more details.
This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the CNS sector. The report includes unique sales forecasts by major product.
The Central Nervous System (CNS) market is the second largest therapeutic category and is one of the fastest growing. We forecast the global CNS market generated sales of US$68.7 billion in 2005 (+6.1% from 2004). The majority of sales were derived from the US (c. 66%) although sales growth was stronger ex-US.
Within this market the largest segments by sales are: antidepressants (23% market share), antipsychotics (22.6%) and anti-epileptics (16.8%). Some of the fastest growing segments are: sleep disorders (+14.8% (YoY), attention deficit hyperactivity disorder (+10.8% YoY), Alzheimer's disease (+10.7% YoY) and antipsychotics (+10.2% YoY).
CNS disorders represent more than 15% of the global cost of disease. For example, costs of over $100 billion per annum makes Alzheimer's the third most expensive disease in the USA. In addition, they are the leading cause of disability; at any one time 1.5 billion people suffer with a brain or spinal disorder.
CNS diseases and disorders represent the largest and fastest growing area of unmet medical need. Over 1.5 billion people worldwide, including over 100 million people in the US, suffer from CNS diseases or disorders. Key prevalence indicators:
Alzheimer's disease: Almost 5 million individuals in the US alone currently suffer from AD and the US Alzheimer's Association estimates that by 2025, over 22 million people worldwide will be afflicted with AD.
Dementia: Approximately 18 million people suffer with dementia worldwide and this figure is expected to increase to 34 million by 2025.
Muiltiple sclerosis: It is estimated that approximately 3 million live with MS worldwide; over 350,000 Americans (approximately 1 in 1000 aged over 30 years) live with multiple sclerosis.
Whilst we anticipate antidepressants will to continue to command the largest percentage of the CNS market, revenue growth will slow as many of the leading brands face generic competition. Newer products such as DVS 233 (Wyeth) and saredutant (sanofi-aventis) will enter the market from 2006 and enable new pharma players to penetrate this multi billion dollar arena.
Answering key business questions
-What marketing challenges does Wyeth face if they are to migrate Effecor patients to DVS 233 before generic competition starts in 2008?
-Pfizer is well placed to become a player in the insomnia market with indiplon -- what are the estimated financial rewards?
Topics Covered:
-Current Market Size -Addressable Patient Population -Current Treatments -Sales Drivers -Sales Breakers -Future Treatments - Early Stage -Market Dynamics - Winners and Losers -Key launches to 2011 -Competitor Ratio Analysis - Products -Competitor Ratio Analysis - Companies -Competitor Ratio Analysis - Drugs
Companies and Products Mentioned:
- Alzhemed (Neurochem) - Asenapine (Pfizer/Organon) - Bifeprunox (Wyeth/Solvay/Lundbeck) - Champix (Pfizer) - Daytrana (Shire) - DVS 233 ( Wyeth) - Flurizan (Myriad Genetics) - Gaboxodol (Lundbeck/Merck) - Indiplon (Pfizer /Neurocrine) - Laquinimod (Teva/Active Biotech) - Lunesta/Estorra (Sepracor) - Lurasidone (Dainippon Sumitomo Pharma/Merck & Co) - Lyrica (Pfizer) - Mylinax (Serono/Ivax) - NS2359 (GlaxoSmithKline/NeuroSearch) - Paliperidone (Johnson & Johnson) - Phenserine (Axonyx) - Rozerem (Takeda) - Saredutant (Sanofi-Aventis)
For more information visit http://www.researchandmarkets.com/reports/c45631
Source: Business Wire
Related Articles
- Honeywell Reports Third Quarter Sales of $7.7 Billion and Earnings of $0.80 Per Share
- Honeywell Reports Second Quarter Sales of $7.6 Billion and Earnings Per Share of $0.60
- Honeywell Reports First Quarter Sales of $7.6 Billion; Earnings of $0.54 Per Share
- Grainger Reports Record Sales of $6.9 Billion and Earnings Per Share of $6.04 for the Year Ended December 31, 2008
- China Nutrition Market Report 2007 Report Reveals That China's Domestic Supplement Market Expanded to $6.7 Billion in 2006
- Infonetics Research: WiMAX Equipment Sales Jump 59%, Motorola Takes the Lead in Worldwide Market Share in 1Q
- Actelis Networks Appoints Mehmet Balos to President of Worldwide Marketing, Sales and Services
- Pharma Marketing & Sales (PMS) 500 Attendee Conference Final Delegate List Published One Week Before April 4-5 Show In New Brunswick, NJ
- Pharma Marketing & Sales (PMS) Conference Attendee List Published in Final Announcement Before April 4-5 Gala Event in New Brunswick, NJ
- Alzheimer's Disease Market in the Seven Major Markets is Worth $6.1 Billion in the Year 2005 and is Forecast to Increase to $7.8 Billion By the Year 2010
 |
 |
User Comments (0)
RSS Feeds